- SinglePoint
recently launched Phyto-Bites product to help pets – particularly dogs –
deal with stress, pain and separation anxiety
- The
company anticipates building on its vertical acquisition strategy in 2019
to capitalize on federal hemp legalization
- Market
forecasts anticipate U.S. pet industry expenditures, which would include
therapeutic products, to more than double within the next few years
Pet owners looking for natural therapies to help their
four-legged loved ones through bouts of pain and anxiety are gaining an
increasing array of options as the cannabis revolution opens the doors to new
product research, including therapeutics for animals. Now, SinglePoint Inc.
(OTCQB: SING), a diversified holding company specializing in M&A activity
that promotes new technologies, finds itself among a competitive field that’s
wild about cannabidiol (CBD) therapeutics for pets as cannabis legalization continues
to advance, as noted in a report by Investorideas.com (http://ibn.fm/Mmyyx).
SinglePoint subsidiary SingleSeed.com recently launched its Phyto-Bites product as a brand formulated to reduce
stress, pain, separation anxiety and inflammation – particularly for dogs. The
company is working with manufacturer CBD Unlimited (formerly Endexx) to
distribute the product online and in stores across the nation.
“We are very excited to add this to our list of products.
The pet market is a tremendous opportunity and we plan to attend and use all
our contacts to promote this product at every opportunity we are presented
with,” SinglePoint CEO Greg Lambrecht stated in the report.
“We love our pets. Raising pets like they are members
of our families means we go the extra mile for them. Especially when it
comes time to address their health problems,” the company states in its
blog (http://ibn.fm/DOzsT).
“More and more pet owners are turning to CBD to help their buddies in similar
fashions.”
The Investorideas.com report cites forecasts from the
American Pet Products Association and New Frontier Data predicting that U.S.
pet industry expenditures will grow from over $72 billion last year to $202.6
billion by 2025, with a five-year CAGR of 57 percent by 2022.
The states’ rights movements of recent years led to a
spreading legalization of “medical marijuana” and, in a few cases, recreational
drug use, despite federal drug policy outlawing it. The movement was emboldened
when a cannabis-based pharmaceutical received federal Food and Drug
Administration approval last year, and then Congress passed legislation
allowing hemp to be grown commercially in the United States without drug
control oversight, even though the FDA continues to require regulatory
oversight for CBD use in food products.
“Selling unapproved products with unsubstantiated
therapeutic claims is not only a violation of the law, but also can put
patients at risk, as these products have not been proven to be safe or
effective,” FDA Commissioner Scott Gottlieb stated in a release (http://ibn.fm/Hh735). “At the
same time, we recognize the potential opportunities that cannabis or
cannabis-derived compounds could offer and acknowledge the significant interest
in these possibilities. We’re committed to pursuing an efficient regulatory
framework for allowing product developers that meet the requirements under our
authorities to lawfully market these types of products.”
SinglePoint is exploring opportunities to produce industrial
hemp through joint venture opportunities with agricultural growers. The company
has also placed an investment in a program that would grow hemp strains of CBD
in a photobioreactor as an initiative to reduce the cost and time involved in
making a potentially pharmaceutical-grade product.
“We are excited for these new opportunities in the hemp
market and have been preparing the company to be in a position in the event the
2018 Farm Bill passed. Now that it has, it’s a matter of closing on the
negotiations we have started,” Lambrecht stated in December (http://ibn.fm/80ZRw). “I intend
and plan for SinglePoint to be a key player in the distribution of hemp
products and sourcing the best products we can in the market.”
“2019 will be a banner year for SinglePoint we are equipped
with the proper funding, partners and opportunities to be firing on all
cylinders,” he added on January 10 (http://ibn.fm/aSHqc). “We as a team expect to position
SingleSeed and SinglePoint as market leads in the CBD market while continuing
to enable founders of the companies we have acquired to grow their businesses.”
For more information, visit the company’s website at www.SinglePoint.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment